Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Clinical manifestations and diagnostic evaluation of benign prostatic hyperplasia

Glenn R Cunningham, MD
Dov Kadmon, MD
Section Editor
Michael P O'Leary, MD, MPH
Deputy Editor
Wenliang Chen, MD, PhD


Benign prostatic hyperplasia (BPH) is a common disorder that increases in frequency progressively with age in men older than 50 years (figure 1). The clinical manifestations and the diagnostic approach to patients suspected of having BPH will be reviewed here. The epidemiology, pathogenesis and treatment of this disorder, and lower urinary tract symptoms in men and acute urinary retention are discussed separately. (See "Epidemiology and pathogenesis of benign prostatic hyperplasia" and "Medical treatment of benign prostatic hyperplasia" and "Transurethral procedures for treating benign prostatic hyperplasia" and "Lower urinary tract symptoms in men" and "Acute urinary retention".)


The prevalence of moderate-to-severe lower urinary tract symptoms (LUTS) and decreased peak urinary flow rates increases with age, and there is a modest correlation among LUTS, peak flow rates, and prostate volume. (See "Epidemiology and pathogenesis of benign prostatic hyperplasia", section on 'Prevalence' and "Lower urinary tract symptoms in men", section on 'Prevalence'.)

In a small percentage of men, untreated BPH can cause acute urinary retention, recurrent urinary tract infections, hydronephrosis, and even renal failure. It is estimated that a 60 year old man with moderate-to-severe symptoms would have a 13.7 percent chance of developing acute urinary retention in the following 10 years. Age, symptoms, urinary flow rate, and prostate volume are risk factors for acute urinary retention at least in population-based studies, though not in all clinical trials [1]. Men with symptomatic BPH who are not treated have about a 2.5 percent per-year risk of developing acute urinary retention [2,3]. (See "Acute urinary retention".)

The natural history of BPH has been examined both in population-based studies and by looking at outcomes in the placebo arms of clinical trials. However, studies have found that outcomes among patients in the placebo arms of clinical trials may not accurately reflect outcomes in the general population [4]. In clinical trials, measurements of LUTS and peak urine flow tend to show a regression to the mean; whereas, this is not seen with measurements of prostate volume and PSA [5]. A systematic review of the placebo arms of 16 randomized trials of medical treatment lasting for one to four years found that the risk of surgery ranged from 1 to 10 percent, and the risk of acute urinary retention ranged from 0.4 to 6.0 percent [6]. Patients experience some progression in symptoms, increase in prostate volume, and decrease in peak urine flow rate that can result in a need for invasive treatment.

Men may or may not have progressive symptoms. In one study, for example, about one-third of men had a 50 percent reduction in the severity of their symptoms of urinary obstruction when followed with no treatment for 2.5 to 5 years after symptom onset [7]. On the other hand, many men have progressive disease that eventually requires treatment [8]. In a prospective study of 1057 men, over 30 years of follow-up, 527 (50 percent) were given a diagnosis of BPH and 110 (10 percent) underwent prostatectomy [9]. The Health Professionals Follow-up Study provides the largest and longest evaluation of LUTS in men ages 40 to over 75 [10]. Participants completed and mailed the International Prostate Symptom Score (IPSS) (table 1) every two years from 1992 to 2008. The study found that progression rates rise steeply as men age. Investigators in the Florey Adelaide Male Ageing Study conducted a five-year follow-up of 780 men between the ages of 35 and 80 years at baseline [11]. They found that storage and voiding lower urinary tract symptoms progressed in 39.8 and 32.3 percent, and improved in 33.1 and 23.4 percent, respectively. Older age, previous diagnosis of BPH or erectile dysfunction, and lower high-density lipoprotein (HDL) cholesterol, testosterone, and income predicted progression of LUTS. Increased physical activity and use of an alpha-blocker and/or a 5-alpha-reductase inhibitor improved symptoms.


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2016. | This topic last updated: Aug 20, 2015.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
  1. O'Leary MP, Wei JT, Roehrborn CG, et al. Correlation of the International Prostate Symptom Score bother question with the Benign Prostatic Hyperplasia Impact Index in a clinical practice setting. BJU Int 2008; 101:1531.
  2. Barry M, Roehrborn C. Management of benign prostatic hyperplasia. Annu Rev Med 1997; 48:177.
  3. Marberger MJ, Andersen JT, Nickel JC, et al. Prostate volume and serum prostate-specific antigen as predictors of acute urinary retention. Combined experience from three large multinational placebo-controlled trials. Eur Urol 2000; 38:563.
  4. Roberts RO, Lieber MM, Jacobson DJ, et al. Limitations of using outcomes in the placebo arm of a clinical trial of benign prostatic hyperplasia to quantify those in the community. Mayo Clin Proc 2005; 80:759.
  5. Roehrborn CG. Definition of at-risk patients: baseline variables. BJU Int 2006; 97 Suppl 2:7.
  6. Emberton M, Fitzpatrick JM, Garcia-Losa M, et al. Progression of benign prostatic hyperplasia: systematic review of the placebo arms of clinical trials. BJU Int 2008; 102:981.
  7. Isaacs JT. Importance of the natural history of benign prostatic hyperplasia in the evaluation of pharmacologic intervention. Prostate Suppl 1990; 3:1.
  8. Jacobsen SJ, Bergstralh EJ, Katusic SK, et al. Screening digital rectal examination and prostate cancer mortality: a population-based case-control study. Urology 1998; 52:173.
  9. Arrighi HM, Metter EJ, Guess HA, Fozzard JL. Natural history of benign prostatic hyperplasia and risk of prostatectomy. The Baltimore Longitudinal Study of Aging. Urology 1991; 38:4.
  10. Platz EA, Joshu CE, Mondul AM, et al. Incidence and progression of lower urinary tract symptoms in a large prospective cohort of United States men. J Urol 2012; 188:496.
  11. Martin S, Lange K, Haren MT, et al. Risk factors for progression or improvement of lower urinary tract symptoms in a prospective cohort of men. J Urol 2014; 191:130.
  12. Marshall LM, Holton KF, Parsons JK, et al. Lifestyle and health factors associated with progressing and remitting trajectories of untreated lower urinary tract symptoms among elderly men. Prostate Cancer Prostatic Dis 2014; 17:265.
  13. Pienta KJ, Esper PS. Risk factors for prostate cancer. Ann Intern Med 1993; 118:793.
  14. Schenk JM, Kristal AR, Arnold KB, et al. Association of symptomatic benign prostatic hyperplasia and prostate cancer: results from the prostate cancer prevention trial. Am J Epidemiol 2011; 173:1419.
  15. Oelke M, Bachmann A, Descazeaud A, et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 2013; 64:118.
  16. Madersbacher S, Pycha A, Klingler CH, et al. The International Prostate Symptom score in both sexes: a urodynamics-based comparison. Neurourol Urodyn 1999; 18:173.
  17. McConnell JD, Barry MJ, Bruskewitz RC. Benign prostatic hyperplasia: diagnosis and treatment. Agency for Health Care Policy and Research. Clin Pract Guidel Quick Ref Guide Clin 1994; :1.
  18. McVary KT, Roehrborn CG, Avins AL, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol 2011; 185:1793.
  19. Wilt TJ, N'Dow J. Benign prostatic hyperplasia. Part 1--diagnosis. BMJ 2008; 336:146.
  20. Parsons JK, Carter HB, Partin AW, et al. Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab 2006; 91:2562.
  21. Bang WJ, Lee JY, Koo KC, et al. Is type-2 diabetes mellitus associated with overactive bladder symptoms in men with lower urinary tract symptoms? Urology 2014; 84:670.
  22. Rosen R, Altwein J, Boyle P, et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 2003; 44:637.
  23. Vallancien G, Emberton M, Harving N, et al. Sexual dysfunction in 1,274 European men suffering from lower urinary tract symptoms. J Urol 2003; 169:2257.
  24. Li MK, Garcia LA, Rosen R. Lower urinary tract symptoms and male sexual dysfunction in Asia: a survey of ageing men from five Asian countries. BJU Int 2005; 96:1339.
  25. Barry MJ, Fowler FJ Jr, O'Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992; 148:1549.
  26. Barry MJ, Fowler FJ, Chang Y, et al. The American Urological Association symptom index: does mode of administration affect its psychometric properties? J Urol 1995; 154:1056.
  27. Lepor H, Nieder A, Feser J, et al. Total prostate and transition zone volumes, and transition zone index are poorly correlated with objective measures of clinical benign prostatic hyperplasia. J Urol 1997; 158:85.
  28. Kojima M, Naya Y, Inoue W, et al. The American Urological Association symptom index for benign prostatic hyperplasia as a function of age, volume and ultrasonic appearance of the prostate. J Urol 1997; 157:2160.
  29. Wadie BS, Ibrahim EH, de la Rosette JJ, et al. The relationship of the International Prostate Symptom Score and objective parameters for diagnosing bladder outlet obstruction. Part I: when statistics fail. J Urol 2001; 165:32.
  30. van Venrooij GE, van Melick HH, Eckhardt MD, Boon TA. Diagnostic and predictive value of voiding diary data versus prostate volume, maximal free urinary flow rate, and Abrams-Griffiths number in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology 2008; 71:469.
  31. Bright E, Cotterill N, Drake M, Abrams P. Developing and validating the International Consultation on Incontinence Questionnaire bladder diary. Eur Urol 2014; 66:294.
  32. Leissner KH, Tisell LE. The weight of the human prostate. Scand J Urol Nephrol 1979; 13:137.
  33. Mohr DN, Offord KP, Melton LJ 3rd. Isolated asymptomatic microhematuria: a cross-sectional analysis of test-positive and test-negative patients. J Gen Intern Med 1987; 2:318.
  34. Ezz el Din K, Koch WF, de Wildt MJ, et al. The predictive value of microscopic haematuria in patients with lower urinary tract symptoms and benign prostatic hyperplasia. Eur Urol 1996; 30:409.
  35. Foley SJ, Soloman LZ, Wedderburn AW, et al. A prospective study of the natural history of hematuria associated with benign prostatic hyperplasia and the effect of finasteride. J Urol 2000; 163:496.
  36. Miller MI, Puchner PJ. Effects of finasteride on hematuria associated with benign prostatic hyperplasia: long-term follow-up. Urology 1998; 51:237.
  37. Coley CM, Barry MJ, Fleming C, Mulley AG. Early detection of prostate cancer. Part I: Prior probability and effectiveness of tests. The American College of Physicians. Ann Intern Med 1997; 126:394.
  38. Roehrborn CG, Boyle P, Gould AL, Waldstreicher J. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology 1999; 53:581.
  39. Hochberg DA, Armenakas NA, Fracchia JA. Relationship of prostate-specific antigen and prostate volume in patients with biopsy proven benign prostatic hyperplasia. Prostate 2000; 45:315.
  40. Marks LS, Roehrborn CG, Andriole GL. Prevention of benign prostatic hyperplasia disease. J Urol 2006; 176:1299.
  41. Carter HB, Landis P, Wright EJ, et al. Can a baseline prostate specific antigen level identify men who will have lower urinary tract symptoms later in life? J Urol 2005; 173:2040.
  42. Mao Q, Zheng X, Jia X, et al. Relationships between total/free prostate-specific antigen and prostate volume in Chinese men with biopsy-proven benign prostatic hyperplasia. Int Urol Nephrol 2009; 41:761.
  43. Dicuio M, Vesely S, Knutson T, et al. Is it possible to predict post-residual voided urine by bladder scan before uroflowmetry--a useful and timesaving test to reduce the number of non--evaluable uroflow measurements? Arch Ital Urol Androl 2010; 82:100.
  44. DiMare JR, Fish SR, Harper JM, et al. Residual urine in normal male subjects. J Urol 1963; 96:180.
  45. Wasson JH, Reda DJ, Bruskewitz RC, et al. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate. N Engl J Med 1995; 332:75.
  46. McLoughlin J, Gill KP, Abel PD, Williams G. Symptoms versus flow rates versus urodynamics in the selection of patients for prostatectomy. Br J Urol 1990; 66:303.
  47. Bundrick TJ, Katz PG. Excretory urography in patients with prostatism. AJR Am J Roentgenol 1986; 147:957.
  48. Corica FA, Jacobsen SJ, King BF, et al. Prostatic central zone volume, lower urinary tract symptom severity and peak urinary flow rates in community dwelling men. J Urol 1999; 161:831.
  49. Lieber MM, Rhodes T, Jacobson DJ, et al. Natural history of benign prostatic enlargement: long-term longitudinal population-based study of prostate volume doubling times. BJU Int 2010; 105:214.
  50. Stravodimos KG, Petrolekas A, Kapetanakis T, et al. TRUS versus transabdominal ultrasound as a predictor of enucleated adenoma weight in patients with BPH: a tool for standard preoperative work-up? Int Urol Nephrol 2009; 41:767.
  51. Noworolski SM, Vigneron DB, Chen AP, Kurhanewicz J. Dynamic contrast-enhanced MRI and MR diffusion imaging to distinguish between glandular and stromal prostatic tissues. Magn Reson Imaging 2008; 26:1071.